Avivagen Inc V.VIV.H

VIV has not been profitable since amalgamation in 2005.

[DrJayser]

The Corporation has a history of operating losses. It expects to incur net losses and may never achieve or maintain profitability. The Corporation has not been profitable since amalgamation in 2005. Under International Financial Reporting Standards, as of October 31, 2019, the Corporation had an accumulated deficit of approximately $31 million. The Corporation has not generated any significant revenue from product sales to date and it is possible that it will never have sufficient product sales revenue to achieve profitability. The Corporation might continue to incur losses for the next several years in pursuit of commercialization. To become profitable, the Corporation must successfully develop, manufacture and market its current products as well as continue to identify, develop, manufacture and market new product candidates. It is possible that the Corporation will never have significant product sales revenue. If funding is insufficient at any time in the future, the Corporation may not be able to develop or commercialize its products, take advantage of business opportunities, or respond to competitive pressures. The Corporation’s technology and products are not yet commercially successful While the Corporation believes there is scientific merit to its discoveries they are not yet successfully commercialized to the point of extensive sales or profitability. Avivagen’s products or technologies might Page 24 of 49 not prove sufficiently compelling to potential distributors and end-customers in light of other products available now or in the future. Specifically, pet owners may choose to use pet supplements that have no scientific basis but more aggressive marketing programs. Livestock producers may choose to continue using antibiotics to promote growth and to prevent disease – even in the face of pressure to adopt alternative solutions. OxC-beta™ could prove unable to compete against such factors. Existing customers may not increase their purchases of the Corporation’s products or may cease doing business with the Corporation, which may have an adverse impact on the Corporation’s business and financial condition. The Corporation may need to raise additional capital. The need for capital may require the Corporation to: • engage in equity financings that could result in significant dilution to existing investors; • delay or reduce the scope of or eliminate one or more development programs; • obtain funds through arrangements with collaborators or others that may require the Corporation to relinquish rights to technologies, product candidates or products that the Corporation would otherwise seek to develop or commercialize; or license rights to technologies, product candidates or products on terms that are less favourable than might otherwise be available; • considerably reduce operations; or • cease operations.